{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,28]],"date-time":"2026-07-28T02:54:21Z","timestamp":1785207261215,"version":"3.55.0"},"reference-count":13,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2026,1,8]],"date-time":"2026-01-08T00:00:00Z","timestamp":1767830400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,1,8]],"date-time":"2026-01-08T00:00:00Z","timestamp":1767830400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Clin Microbiol Infect Dis"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1007\/s10096-025-05398-w","type":"journal-article","created":{"date-parts":[[2026,1,7]],"date-time":"2026-01-07T23:26:36Z","timestamp":1767828396000},"page":"1483-1489","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["In vitro interactions of sulbactam\/durlobactam in combination with meropenem, ceftazidime\/avibactam, piperacillin\/tazobactam, cefiderocol and fosfomycin against carbapenem-resistant Acinetobacter baumannii (CRAB) clinical isolates"],"prefix":"10.1007","volume":"45","author":[{"given":"Giulia","family":"Zocche","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Russell E.","family":"Lewis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriele","family":"Bianco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlo","family":"Tascini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paolo","family":"Gaibani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,1,8]]},"reference":[{"key":"5398_CR1","doi-asserted-by":"publisher","first-page":"826","DOI":"10.1111\/j.1469-0691.2006.01456.x","volume":"12","author":"L Poirel","year":"2006","unstructured":"Poirel L, Nordmann P (2006) Carbapenem resistance in Acinetobacter baumannii: mechanisms and epidemiology. Clin Microbiol Infect 12:826\u2013836","journal-title":"Clin Microbiol Infect"},{"key":"5398_CR2","unstructured":"WHO updates list of drug-resistant bacteria most threatening to human health. (Available at: https:\/\/www.who.int\/news\/item\/17-05-2024-who-updates-list-of-drug-resistant-bacteria-most-threatening-to-human-health)"},{"key":"5398_CR3","doi-asserted-by":"publisher","first-page":"e01612","DOI":"10.1128\/AAC.01612-17","volume":"61","author":"AB Shapiro","year":"2017","unstructured":"Shapiro AB (2017) Kinetics of sulbactam hydrolysis by \u03b2-lactamases, and kinetics of \u03b2-lactamase inhibition by sulbactam. Antimicrob Agents Chemother 61:e01612-e1617","journal-title":"Antimicrob Agents Chemother"},{"key":"5398_CR4","doi-asserted-by":"publisher","first-page":"17104","DOI":"10.1038\/nmicrobiol.2017.104","volume":"2","author":"TF Durand-R\u00e9ville","year":"2017","unstructured":"Durand-R\u00e9ville TF, Guler S, Comita-Prevoir J, Chen B, Bifulco N, Huynh H et al (2017) ETX2514 is a broad-spectrum \u03b2-lactamase inhibitor for the treatment of drug-resistant Gram-negative bacteria including Acinetobacter baumannii. Nat Microbiol 2:17104","journal-title":"Nat Microbiol"},{"issue":"7","key":"5398_CR5","doi-asserted-by":"publisher","first-page":"1753","DOI":"10.1007\/s10096-025-05121-9","volume":"44","author":"L Caiazzo","year":"2025","unstructured":"Caiazzo L, Bianco G, Boattini M, Costa C, Gaibani P (2025) Genomic characterization of carbapenem-resistant Acinetobacter baumannii clinical strains resistant to sulbactam\/durlobactam from Italy. Eur J Clin Microbiol Infect Dis 44(7):1753\u20131755. https:\/\/doi.org\/10.1007\/s10096-025-05121-9","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"5398_CR6","doi-asserted-by":"publisher","DOI":"10.3390\/antibiotics11121793","volume":"11","author":"L Principe","year":"2022","unstructured":"Principe L, Di Bella S, Conti J, Perilli M, Piccirilli A, Mussini C, Decorti G (2022) Acinetobacter baumannii resistance to sulbactam\/durlobactam: a systematic review. Antibiotics 11:1793","journal-title":"Antibiotics"},{"key":"5398_CR7","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.ijid.2017.09.017","volume":"65","author":"P Gaibani","year":"2017","unstructured":"Gaibani P, Lewis RE, Volpe SL, Giannella M, Campoli C, Landini MP et al (2017) In vitro interaction of ceftazidime-avibactam in combination with different antimicrobials against KPC-producing Klebsiella pneumoniae clinical isolates. Int J Infect Dis 65:1\u20133","journal-title":"Int J Infect Dis"},{"key":"5398_CR8","doi-asserted-by":"publisher","DOI":"10.1128\/aac.01627-24","volume":"69","author":"B Veeraraghavan","year":"2025","unstructured":"Veeraraghavan B, Shin E, Bakthavatchalam YD, Manesh A, Dubey D, Tascini C et al (2025) A microbiological and structural analysis of the interplay between sulbactam\/durlobactam and imipenem against penicillin-binding proteins (PBPs) of Acinetobacter spp. Antimicrob Agents Chemother 69:e0162724. https:\/\/doi.org\/10.1128\/aac.01627-24","journal-title":"Antimicrob Agents Chemother"},{"key":"5398_CR9","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1097\/QCO.0000000000001148","volume":"38","author":"C Bonazzetti","year":"2025","unstructured":"Bonazzetti C, Giannella M, Pascale R (2025) From clinical trials to daily practice: how to adequately administer sulbactam-durlobactam? Alone or combined with imipenem? Curr Opin Infect Dis 38:579\u2013587. https:\/\/doi.org\/10.1097\/QCO.0000000000001148","journal-title":"Curr Opin Infect Dis"},{"key":"5398_CR10","doi-asserted-by":"publisher","first-page":"1072","DOI":"10.1016\/S1473-3099(23)00184-6","volume":"23","author":"KS Kaye","year":"2023","unstructured":"Kaye KS, Shorr AF, Wunderink RG, Du B, Poirier GE, Rana K et al (2023) Efficacy and safety of sulbactam-durlobactam versus colistin for the treatment of patients with serious infections caused by Acinetobacter baumannii-calcoaceticus complex: a multicentre, randomised, active-controlled, phase 3, non-inferiority clinical trial (ATTACK). Lancet Infect Dis 23:1072\u20131084. https:\/\/doi.org\/10.1016\/S1473-3099(23)00184-6","journal-title":"Lancet Infect Dis"},{"key":"5398_CR11","doi-asserted-by":"publisher","DOI":"10.3390\/antibiotics12121729","volume":"12","author":"A Karruli","year":"2023","unstructured":"Karruli A, Migliaccio A, Pournaras S, Durante-Mangoni E, Zarrilli R (2023) Cefiderocol and sulbactam-durlobactam against carbapenem-resistant Acinetobacter baumannii. Antibiotics 12:1729","journal-title":"Antibiotics"},{"key":"5398_CR12","doi-asserted-by":"publisher","first-page":"2616","DOI":"10.1128\/AAC.01643-07","volume":"52","author":"M Iacono","year":"2008","unstructured":"Iacono M, Villa L, Fortini D, Bordoni R, Imperi F, Bonnal RJ et al (2008) Whole-genome pyrosequencing of an epidemic multidrug-resistant Acinetobacter baumannii strain belonging to the European clone II group. Antimicrob Agents Chemother 52:2616\u20132625. https:\/\/doi.org\/10.1128\/AAC.01643-07","journal-title":"Antimicrob Agents Chemother"},{"key":"5398_CR13","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0001805","volume":"3","author":"D Vallenet","year":"2008","unstructured":"Vallenet D, Nordmann P, Barbe V, Poirel L, Mangenot S, Bataille E et al (2008) Comparative analysis of Acinetobacters: three genomes for three lifestyles. PLoS One 3:e1805. https:\/\/doi.org\/10.1371\/journal.pone.0001805","journal-title":"PLoS One"}],"container-title":["European Journal of Clinical Microbiology & Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10096-025-05398-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10096-025-05398-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10096-025-05398-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,30]],"date-time":"2026-05-30T08:03:57Z","timestamp":1780128237000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10096-025-05398-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,8]]},"references-count":13,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,5]]}},"alternative-id":["5398"],"URL":"https:\/\/doi.org\/10.1007\/s10096-025-05398-w","relation":{},"ISSN":["0934-9723","1435-4373"],"issn-type":[{"value":"0934-9723","type":"print"},{"value":"1435-4373","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,8]]},"assertion":[{"value":"23 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 December 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 January 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}